image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
53fc683fb4dcc66c7b5f3ddbadab4fb700d7d42eae0be3c7fabe882709da5872.png | complex | <table><tr><td> </td><td colspan="2">Standard margin</td><td colspan="2">Reduced margin</td><td> </td><td> </td><td> </td></tr><tr><td>Parameter</td><td>Mean</td><td>St. Dev.</td><td>Mean</td><td>St. Dev.</td><td>Difference (Gy)</td><td>(%)</td><td>p-value</td></tr><tr><td>Max dose (Gy)</td><td>61.4</td><td>1.4</td><td... | <table><tr><td></td><td colspan="2">Standard margin</td><td colspan="2">Reduced margin</td><td></td><td></td><td></td></tr><tr><td>Parameter</td><td>Mean</td><td>St. Dev.</td><td>Mean</td><td>St. Dev.</td><td>Difference (Gy)</td><td>(%)</td><td>p-value</td></tr><tr><td>Max dose (Gy)</td><td>61.4</td><td>1.4</td><td>56.... | <table><tr><td>D60% (Gy)</td><td>32.7</td><td>13.5</td><td>18.7</td><td>10.9</td><td>14.0</td><td>42.9%</td><td><0.001</td></tr><tr><td>D80% (Gy)</td><td>27.3</td><td>12.1</td><td>15.3</td><td>10.0</td><td>12.0</td><td>44.0%</td><td><0.001</td></tr><tr><td>D98% (Gy)</td><td>20.7</td><td>9.3</td><td>11.8</td><td>7.7</td... |
86368ec1cb1e07452ff05e37cb2e59b09581e67612b38eb06bf3aa1a96ae5f28.png | complex | <table><tr><td></td><td colspan="2">PACCE oxaliplatin cohort [43]</td><td colspan="2">CAIRO2 [47]</td></tr><tr><td></td><td colspan="2"> (<i>N</i> = 823)</td><td colspan="2">(<i>N</i> = 755)</td></tr><tr><td></td><td>Ox + Bev + Pmab</td><td>Ox + Bev</td><td>Cap, Ox + Bev + Cmab</td><td>Cap, Ox + Bev</td></tr><tr><td>Me... | <table><tr><td></td><td colspan="2">PACCE oxaliplatin cohort [43]</td><td colspan="2">CAIRO2 [47]</td></tr><tr><td></td><td colspan="2"></td><td colspan="2">(N = </td></tr></table> | <table><tr><td></td><td colspan="2">(N = 823)</td><td colspan="2">755)</td></tr><tr><td></td><td>Ox + Bev + Pmab</td><td>Ox + Bev</td><td>Cap, Ox + Bev + Cmab</td><td>Cap, Ox + Bev</td></tr><tr><td>Median progression-free survival (95% CI), mo</td><td>10.0 (8.9–11.0)</td><td>11.4 (10.5–11.9)</td><td>9.4 (8.4–10.5)</td>... |
3c6b6819c2c86dbcde79f00f776a2091c9f0979cac55918e4cc013896e399568.png | complex | <table><tr><td>Name</td><td>Sequence</td><td>Description</td></tr><tr><td><i>NIP5;1_qRT-PCR-1</i></td><td>caccgattttccctctcctgat</td><td rowspan="10">Probes for realtime PCR</td></tr><tr><td><i>NIP5;1_qRT-PCR-2</i></td><td>ctctttcttactctctagcctc</td></tr><tr><td><i>NIP5;1_qRT-PCR-3</i></td><td>gaatgttcccacgaactcgg</td>... | <table><tr><td>Name</td><td>Sequence</td><td>Description</td></tr><tr><td>NIP5;1_qRT-PCR-1</td><td>caccgattttccctctcctgat</td><td rowspan="2">Probes for realtime PCR</td></tr><tr><td>NIP5;1_qRT-PCR-2</td><td>ctctttcttactctctagcctc</td></tr></table> | <table><tr><td>NIP5;1_qRT-PCR-3</td><td>gaatgttcccacgaactcgg</td><td rowspan="8">Probes for realtime PCR</td></tr><tr><td>NIP5;1_qRT-PCR-4</td><td>acattcatcttgatattcacc</td></tr><tr><td>NIP5;1_qRT-PCR-5</td><td>gcatgcagcgttaccgatta</td></tr><tr><td>PP2A_qRT-PCR-1</td><td>ccatgtttgaggatcttacgc</td></tr><tr><td>PP2A_qRT-... |
6cf2b3a4f5e9b1e3668d41787799866e33baea85ee3398544f79d2f6d1b52da8.png | simple | <table><tr><td>sCr (mg/dl)</td><td>AKI group</td><td>non-AKI group</td><td><i>P</i> value</td></tr><tr><td></td><td>(<i>n</i> = 11)</td><td>(<i>n</i> = 39)</td><td></td></tr><tr><td>Preoperative</td><td>0.72 ± 0.14</td><td>0.68 ± 0.15</td><td>0.531</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td... | <table><tr><td>sCr (mg/dl)</td><td>AKI group</td><td>non-AKI group</td><td>P value</td></tr><tr><td></td><td>(n = 11)</td><td>(n = 39)</td><td></td></tr><tr><td>Preoperative</td><td>0.72 ± 0.14</td><td>0.68 ± 0.15</td><td>0.531</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>0.8... | <table><tr><td>sCr (mg/dl)</td><td>AKI group</td><td>non-AKI group</td><td>P value</td></tr><tr><td></td><td>(n = 11)</td><td>(n = 39)</td><td></td></tr><tr><td>2 days</td><td>1.04 ± 0.15</td><td>0.78 ± 0.19</td><td><0.01</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td></tr><tr><td>3 days</td><td>1.05 ± 0... |
782b33f1060d8206fde9e0d3df4f2b0cb56713f56ea20830ea3a3ca267a45e06.png | complex | <table><tr><td colspan="2">Germplasm or genotypes</td><td>Sites (No)</td><td>Reference</td></tr><tr><td>Type</td><td>Number</td><td></td><td></td></tr><tr><td>Natural accession</td><td>124</td><td>1</td><td>Mengesha et al. (1965)</td></tr><tr><td>Hybrids</td><td>559</td><td>1</td><td>Berhe et al. (1989a,b,c)</td></tr><... | <table><tr><td colspan="2">Germplasm or genotypes</td><td>Sites (No)</td><td>Reference</td></tr><tr><td>Type</td><td>Number</td><td></td><td></td></tr><tr><td>Natural accession</td><td>124</td><td>1</td><td>Mengesha et al. (1965)</td></tr><tr><td>Hybrids</td><td>559</td><td>1</td><td>Berhe et al. (1989a,b,c)</td></tr><... | <table><tr><td colspan="2">Germplasm or genotypes</td><td>Sites (No)</td><td>Reference</td></tr><tr><td>Type</td><td>Number</td><td></td><td></td></tr><tr><td>Natural accession</td><td>15</td><td>1</td><td>Plaza-Wüthrich et al. (2013)</td></tr><tr><td>Natural accession</td><td>81</td><td>1</td><td>Lule and Mengistu (2... |
9897bcf2700a8688846a677b613d7741670bab3877d817b39c784bb3d77835e6.png | complex | <table><tr><td>Variables</td><td>Categories</td><td colspan="8">Asthma confirmed by BHR</td></tr><tr><td></td><td></td><td colspan="4">Crude model</td><td colspan="4">Adjusted model</td></tr><tr><td></td><td></td><td>PR</td><td colspan="2">95 % CI</td><td><i>p</i> value</td><td>PR</td><td colspan="2">95 % CI</td><td><i... | <table><tr><td>Variables</td><td>Categories</td><td>Asthma confirmed by BHR</td></tr><tr><td></td><td></td><td>Crude model</td></tr><tr><td></td><td></td><td>PR</td></tr><tr><td>Group</td><td>Exposed vs Non-exposed</td><td>1.08</td></tr><tr><td>Endotoxin levels</td><td>Low vs High</td><td>1.21</td></tr><tr><td>Institut... | <table><tr><td colspan="7">Asthma confirmed by BHR</td></tr><tr><td colspan="3">Crude model</td><td colspan="4">Adjusted model</td></tr><tr><td colspan="2">95 % CI</td><td>p value</td><td>PR</td><td colspan="2">95 % CI</td><td>p value</td></tr><tr><td>0.69</td><td>1.68</td><td>0.73</td><td>1.12</td><td>0.71</td><td>1.7... |
1841538fa54707869d10914dda7789933d3772d8821dc739cd76d069ac621500.png | simple | <table><tr><td></td><td>ADHD group(<i>n </i>= 16)</td><td>Control group(<i>n </i>= 16)</td><td>Group differences<sup>a</sup></td></tr><tr><td></td><td>M (SD)</td><td>M (SD)</td><td></td></tr><tr><td>Age (years)</td><td>10.7 (1.6)</td><td>10.2 (1.3)</td><td>ns</td></tr><tr><td>IQ (WISC-III)</td><td>97.1 (14.2)</td><td>1... | <table><tr><td></td><td>ADHD group(n = 16)</td><td>Control group(n = 16)</td><td>Group differencesa</td></tr><tr><td></td><td>M (SD)</td><td>M (SD)</td><td></td></tr><tr><td>Age (years)</td><td>10.7 (1.6)</td><td>10.2 (1.3)</td><td>ns</td></tr><tr><td>IQ (WISC-III)</td><td>97.1 (14.2)</td><td>102.7 (9.5)</td><td>ns</td... | <table><tr><td></td><td>ADHD group(n = 16)</td><td>Control group(n = 16)</td><td>Group differencesa</td></tr><tr><td></td><td>M (SD)</td><td>M (SD)</td><td></td></tr><tr><td>RT hits monetary reward</td><td>454.4 (80.4)</td><td>416.8 (58.4)</td><td>ns</td></tr><tr><td>RT false alarms baseline</td><td>355.2 (75.5)</td><t... |
8979775de6e6d790dd71d4b6ef5b196298df66bfc293f7e8dcf1b75f1f012678.png | complex | <table><tr><td>Fracture sites</td><td>No. of fractures</td><td>Fracture IR (/1000 PY)</td><td>Age/sex adjusted HR (95 % CI)</td><td>Adjusted HR (95 % CI)</td></tr><tr><td colspan="5">Major osteoporotic fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>4373</td><td>6.1</td><td>Reference</td><td>Reference<... | <table><tr><td>Fracture sites</td><td>No. of fractures</td><td>Fracture IR (/1000 PY)</td><td>Age/sex adjusted HR (95 % CI)</td><td>Adjusted HR (95 % CI)</td></tr><tr><td colspan="5">Major osteoporotic fracture</td></tr><tr><td>Never-GLP1-ra usea</td><td>4373</td><td>6.1</td><td>Reference</td><td>Reference</td></tr><tr... | <table><tr><td>rent GLP1-ra use</td><td></td><td>3</td><td>.47–1.32)</td><td>0.82 (0.48–1.37)d</td></tr><tr><td colspan="5">Vertebral fracture</td></tr><tr><td>Never-GLP1-ra usea</td><td>513</td><td>0.7</td><td>Reference</td><td>Reference</td></tr><tr><td>Current GLP1-ra use</td><td>8</td><td>0.7</td><td>1.59 (0.78–3.2... |
de08d6f43d8f83c166735facfeeddc1b203ec5660a4a5111cd5036af9f33ee8e.png | complex | <table><tr><td></td><td></td><td></td><td colspan="3">Age</td><td colspan="3">Gender</td></tr><tr><td>EVA derivative</td><td>Intercept</td><td>R<sup>2</sup></td><td>B</td><td>β</td><td>p</td><td>B</td><td>β</td><td><i>p</i></td></tr><tr><td>Prolonged sitting (>30 min)</td><td>−30.6</td><td>.01</td><t... | <table><tr><td></td><td></td><td></td><td colspan="3">Age</td><td colspan="3">Gender</td></tr><tr><td>EVA derivative</td><td>Intercept</td><td>R2</td><td>B</td><td>β</td><td>p</td><td>B</td><td>β</td><td>p</td></tr><tr><td>Prolonged sitting (>30 min)</td><td>−30.6</td><td>.01</td><td>0.00</td><td>0.00</td><td>1.0</td><... | <table><tr><td></td><td></td><td></td><td colspan="3">Age</td><td colspan="3">Gender</td></tr><tr><td>EVA derivative</td><td>Intercept</td><td>R2</td><td>B</td><td>β</td><td>p</td><td>B</td><td>β</td><td>p</td></tr><tr><td>Walking >10 min</td><td>18.3</td><td>.06</td><td>0.05</td><td>0.08</td><td>.25</td><td>−2.47</td>... |
7f03fe2d406922d39e89ca593beab7aea7d5b0c970e4a0d515ba19f5d9f373a9.png | simple | <table><tr><td>Accession no.</td><td>Strain</td><td>BioSample ID</td><td>BioProject ID</td></tr><tr><td>CP018252</td><td>9000</td><td>SAMN05544760</td><td>PRJNA336330</td></tr><tr><td>CP018250</td><td>10671</td><td>SAMN05544761</td><td>PRJNA336330</td></tr><tr><td>CP018247</td><td>7784</td><td>SAMN05544762</td><td>PRJN... | <table><tr><td>Accession no.</td><td>Strain</td><td>BioSample ID</td><td>BioProject ID</td></tr><tr><td>CP018252</td><td>9000</td><td>SAMN05544760</td><td>PRJNA336330</td></tr><tr><td>CP018250</td><td>10671</td><td>SAMN05544761</td><td>PRJNA336330</td></tr><tr><td>CP018247</td><td>7784</td><td>SAMN05544762</td><td>PRJN... | <table><tr><td>Accession no.</td><td>Strain</td><td>BioSample ID</td><td>BioProject ID</td></tr><tr><td>CP018243</td><td>350</td><td>SAMN05544765</td><td>PRJNA336330</td></tr><tr><td>CP018239</td><td>272</td><td>SAMN05544766</td><td>PRJNA336330</td></tr><tr><td>CP018245</td><td>472</td><td>SAMN05544767</td><td>PRJNA336... |
57c97298c16027babe6726ca2058ccf5280ec0b056394e5a0965bf569906f328.png | simple | <table><tr><td><i>n1</i></td><td><i>n2</i></td><td>Ratio</td><td>Distance</td></tr><tr><td>1</td><td>2</td><td>0.50</td><td>1</td></tr><tr><td>2</td><td>3</td><td>0.67</td><td>1</td></tr><tr><td>3</td><td>4</td><td>0.75</td><td>1</td></tr><tr><td>4</td><td>5</td><td>0.80</td><td>1</td></tr><tr><td>5</td><td>6</td><td>0... | <table><tr><td>n1</td><td>n2</td><td>Ratio</td></tr><tr><td>1</td><td>2</td><td>0.50</td></tr><tr><td>2</td><td>3</td><td>0.67</td></tr><tr><td>3</td><td>4</td><td>0.75</td></tr><tr><td>4</td><td>5</td><td>0.80</td></tr><tr><td>5</td><td>6</td><td>0.83</td></tr><tr><td>6</td><td>7</td><td>0.86</td></tr></table> | <table><tr><td>Distance</td></tr><tr><td>1</td></tr><tr><td>1</td></tr><tr><td>1</td></tr><tr><td>1</td></tr><tr><td>1</td></tr><tr><td>1</td></tr></table> |
887450ae95c874b12fd0c8b2d62eb6c37698bb939773802df044dccb91c5dbe0.png | complex | <table><tr><td></td><td>Composition</td><td>Strain-to-failure (mm/mm)</td><td>Stress-at-failure (MPa)</td><td>Toughness (MJ/m<sup>3</sup>)</td></tr><tr><td rowspan="4"><i>T</i> = temperature at loss modulus peak</td><td>5% BPA</td><td>1.43 ± 0.0985</td><td>11.9 ± 2.14</td><td>8.99 ± 1.72</td></tr><tr><td... | <table><tr><td></td><td>Composition</td><td>Strain-to-failure (mm/mm)</td><td>Stress-at-failure (MPa)</td><td>Toughness (MJ/m3)</td></tr><tr><td rowspan="4">T = temperature at loss modulus peak</td><td>5% BPA</td><td>1.43 ± 0.0985</td><td>11.9 ± 2.14</td><td>8.99 ± 1.72</td></tr><tr><td>15% BPA</td><td>0.773 ± 0.0906</... | <table><tr><td rowspan="3">elta peak</td><td>A</td><td>590 ± 0.182</td><td>4</td><td></td></tr><tr><td>25% BPA</td><td>0.357 ± 0.0354</td><td>4.09 ± 0.251</td><td>0.647±0.0723</td></tr><tr><td>35% BPA</td><td>0.376 ± 0.0879</td><td>7.73 ± 1.56</td><td>1.24 ± 0.316</td></tr></table> |
32f0a4ccd8f3903c430f13a002d1ff86186f191c25ea70e76581f604a1f85fc6.png | simple | <table><tr><td> </td><td>PR</td><td>GR</td><td>CS</td><td>OD</td><td>IT</td><td>FL</td></tr><tr><td>PR</td><td>—</td><td>MI</td><td>WI</td><td>EI</td><td>SI</td><td>VSI</td></tr><tr><td>GR</td><td></td><td>—</td><td></td><td>SMI</td><td></td><td></td></tr><tr><td>CS</td><td></td><td>WI</td><td>—</td><... | <table><tr><td></td><td>PR</td><td>GR</td><td>CS</td><td>OD</td><td>IT</td><td>FL</td></tr><tr><td>PR</td><td>—</td><td>MI</td><td>WI</td><td>EI</td><td>SI</td><td>VSI</td></tr><tr><td>GR</td><td></td><td>—</td><td></td><td>SMI</td><td></td><td></td></tr><tr><td>CS</td><td></td><td>WI</td><td>—</td><td></td><td></td><t... | <table><tr><td></td><td>PR</td><td>GR</td><td>CS</td><td>OD</td><td>IT</td><td>FL</td></tr><tr><td>IT</td><td></td><td>SMI</td><td>MI</td><td></td><td>—</td><td></td></tr><tr><td>FL</td><td></td><td>WI</td><td>EI</td><td></td><td>MI</td><td>—</td></tr></table> |
d38de7789e2352444ae7437eed4a53ead45816f1b5ba7ae98058ff2a5c230de2.png | complex | <table><tr><td colspan="4">Locus</td><td colspan="5">Initial Signal</td><td colspan="5">Regional Validation Signal</td></tr><tr><td>Chr</td><td>Position (Mb)</td><td>Gene</td><td>Prior HDL or Lipid Association [Ref]</td><td>Lead SNP</td><td>MA</td><td>MAF</td><td>Effect (mg/dl)</td><td><i>P</i>-value</td><td>Lead SNP</... | <table><tr><td colspan="4">Locus</td><td colspan="2">Initial Signal</td></tr><tr><td>Chr</td><td>Position (Mb)</td><td>Gene</td><td>Prior HDL or Lipid Association [Ref]</td><td>Lead SNP</td><td>MA</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Whites</td></tr><tr><td>1</td><td>185.2</td><td>PLA2G4A</t... | <table><tr><td colspan="3">Initial Signal</td><td colspan="5">Regional Validation Signal</td></tr><tr><td>MAF</td><td>Effect (mg/dl)</td><td>P-value</td><td>Lead SNP</td><td>MA</td><td>MAF</td><td>Effect (mg/dl)</td><td>P-value</td></tr><tr><td colspan="3">Whites</td><td colspan="5">African Americans</td></tr><tr><td>0... |
6ad8352aa5c400319828fa0956916c73cbc27e4ebcb55e665653a5c0ad8e2bb8.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">TNF-α Stimulation (U/ml)</td></tr><tr><td>0</td><td>10</td><td>100</td></tr><tr><td>HUVECs in monocultures</td><td>4.9 ± 1.5</td><td>15.7 ± 0.8*</td><td>24.57 ± 3.01**</td></tr><tr><td>HUVECs in direct contact with podocytes</td><td>11.43 ± 4.7</t... | <table><tr><td rowspan="2"></td><td colspan="3">TNF-α Stimulation (U/ml)</td></tr><tr><td>0</td><td>10</td><td>100</td></tr><tr><td>HUVECs in monocultures</td><td>4.9 ± 1.5</td><td>15.7 ± 0.8*</td><td>24.57 ± 3.01**</td></tr><tr><td>HUVECs in direct contact with podocytes</td><td>11.43 ± 4.7</td><td>21.53 ± 5.7</td><td... | <table><tr><td> direct contact</td><td>13</td><td>± 1.9*</td><td>± 1.6**</td></tr></table> |
7dbd474ee782708a0fa7a54b85612aa415b66230d541f52c19746576350baa36.png | complex | <table><tr><td rowspan="2"></td><td>MD</td><td>Normal LV and RV function</td><td>Impaired LV and/or RV function</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>N</i> = 63</td><td><i>N</i> = 31</td><td><i>N</i> = 32</td></tr><tr><td>Male, <i>n</i> (%)</td><td>63 (100)</td><td>31 (100)</td><td>32 (100)</td><td>1.0... | <table><tr><td rowspan="2"></td><td>MD</td><td>Normal LV and RV function</td><td>Impaired LV and/or RV function</td><td rowspan="2">p value</td></tr><tr><td>N = 63</td><td>N = 31</td><td>N = 32</td></tr><tr><td>Male, n (%)</td><td>63 (100)</td><td>31 (100)</td><td>32 (100)</td><td>1.00</td></tr></table> | <table><tr><td rowspan="2"></td><td>MD</td><td>Normal LV and RV function</td><td>Impaired LV and/or RV function</td><td rowspan="2">p value</td></tr><tr><td>N = 63</td><td>N = 31</td><td>N = 32</td></tr><tr><td>Age, years</td><td>31 ± 15</td><td>27 ± 15</td><td>34 ± 15</td><td>0.11</td></tr><tr><td>BMD, n (%)</td><td>5... |
7e5f9992fc1f71c6cc754bb75cf545e80ead3275ec53f95e57d3423ff2de9a27.png | simple | <table><tr><td>Plasmid</td><td>Description</td><td>Source of reference</td></tr><tr><td>pGK423</td><td>Yeast expression vector containing <i>PGK1</i> promoter, 2 μ origin, <i>HIS3</i> marker, no expression (control plasmid)</td><td>Ishii et al. [10]</td></tr><tr><td>pGK426</td><td>Yeast expression vector containin... | <table><tr><td>Plasmid</td><td>Description</td><td>Source of reference</td></tr><tr><td>pGK423</td><td>Yeast expression vector containing PGK1 promoter, 2 μ origin, HIS3 marker, no expression (control plasmid)</td><td>Ishii et al. [10]</td></tr><tr><td>pGK426</td><td>Yeast expression vector containing PGK1 promoter, 2 ... | <table><tr><td>pATP425-leuC(Mj)-leuD(Mj)</td><td>LEU2, co-expression of M. jannaschii leuC and leuD genes</td><td>This study</td></tr><tr><td>pATP425-cimA-leuC(Cb)-leuD(Cb)</td><td>LEU2, co-expression of M. jannaschii cimA, C. beijerinckii leuC and leuD genes</td><td>This study</td></tr><tr><td>pATP425-cimA-leuC(Ec)-le... |
fb958939ba8537f80aa5dc16bc69e997351c132bbf943b504a6fd8e5382e121b.png | simple | <table><tr><td>Source</td><td>Type III sum of squares</td><td>df</td><td>mean square</td><td>F</td><td>P</td></tr><tr><td>population</td><td>33.571</td><td>1</td><td>33.571</td><td>98.623</td><td>< 0.001</td></tr><tr><td>sex</td><td>12.560</td><td>1</td><td>12.560</td><td>36.899</td><td>< 0.001</td></tr><tr><td>p... | <table><tr><td>Source</td><td>Type III sum of squares</td><td>df</td></tr><tr><td>population</td><td>33.571</td><td>1</td></tr><tr><td>sex</td><td>12.560</td><td>1</td></tr><tr><td>population*sex</td><td>3.830</td><td>1</td></tr><tr><td>flower diameter</td><td>0.104</td><td>1</td></tr><tr><td>error</td><td>187.217</td>... | <table><tr><td>mean square</td><td>F</td><td>P</td></tr><tr><td>33.571</td><td>98.623</td><td>< 0.001</td></tr><tr><td>12.560</td><td>36.899</td><td>< 0.001</td></tr><tr><td>3.830</td><td>11.251</td><td>= 0.001</td></tr><tr><td>0.104</td><td>0.304</td><td>= 0.581</td></tr><tr><td>0.337</td><td></td><td></td></tr></tabl... |
ddc1e05c6f99fb473c7f8ad9f4a99734d3b2618d98ed35a74c32f908f287d6cf.png | complex | <table><tr><td>Antibody(ies)</td><td>Number of patients</td><td>Percentage</td></tr><tr><td colspan="3">Alloantibodies</td></tr><tr><td>Anti-c</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C</td><td>3</td><td>1.9</td></tr><tr><td>Anti-c and anti-E</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C + D</td><td>8</td><td>5.1<... | <table><tr><td>Antibody(ies)</td><td>Number of patients</td><td>Percentage</td></tr><tr><td colspan="3">Alloantibodies</td></tr><tr><td>Anti-c</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C</td><td>3</td><td>1.9</td></tr><tr><td>Anti-c and anti-E</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C + D</td><td>8</td><td>5.1<... | <table><tr><td>Antibody(ies)</td><td>Number of patients</td><td>Percentage</td></tr><tr><td>Auto- + alloanti-S</td><td>1</td><td>0.6</td></tr><tr><td>Not determined</td><td>12</td><td>7.6</td></tr><tr><td>Total</td><td>157</td><td>≈100%</td></tr></table> |
e0392898e7c9e9c53e2fdc24038a41773f86e9d55318c317483fbdeb99e13bdb.png | simple | <table><tr><td>Genotype</td><td>Strain</td><td>Accession number</td><td>Genotype</td><td>Strain</td><td>Accession number</td></tr><tr><td>GI_1</td><td>NV-USA93</td><td>M87661</td><td>GII_6</td><td>SU3-JPN </td><td>AB039776</td></tr><tr><td>GI_2</td><td>SOV-GBR93</td><td>L07418</td><td>GII_7</td><td>GN273-USA93</td><td>... | <table><tr><td>Genotype</td><td>Strain</td><td>Accession number</td><td>Genotype</td><td>Strain</td><td>Accession number</td></tr><tr><td>GI_1</td><td>NV-USA93</td><td>M87661</td><td>GII_6</td><td>SU3-JPN</td><td>AB039776</td></tr><tr><td>GI_2</td><td>SOV-GBR93</td><td>L07418</td><td>GII_7</td><td>GN273-USA93</td><td>A... | <table><tr><td>Genotype</td><td>Strain</td><td>Accession number</td><td>Genotype</td><td>Strain</td><td>Accession number</td></tr><tr><td>GI_6</td><td>BS5-GER</td><td>AF093797</td><td>GII_11</td><td>SW918-JPN97</td><td>AB074893</td></tr><tr><td>GI_7</td><td>Wnchest-GBR94</td><td>AJ277609</td><td>GII_12</td><td>Gifu-JPN... |
96571da16e013dba98706c25f7499c3575136d33ec53716a39a275558c4c12cd.png | complex | <table><tr><td>Characteristic</td><td>Bipolar I(<i>n</i> = 1809)</td><td>Bipolar II(<i>n</i> = 922)</td><td>Total(<i>N</i> = 2731)</td></tr><tr><td colspan="4">Gender, <i>n</i> (%)</td></tr><tr><td> Male</td><td>752 (41.6)</td><td>340 (36.9)</td><td>1092 (40.0)</td></tr><tr><td> Female</td><td>1057 (58.4)</td><td>582 (... | <table><tr><td>Characteristic</td><td>Bipolar I(n = 1809)</td><td>Bipolar II(n = 922)</td><td>Total(N = 2731)</td></tr></table> | <table><tr><td colspan="4">Gender, n (%)</td></tr><tr><td>Male</td><td>752 (41.6)</td><td>340 (36.9)</td><td>1092 (40.0)</td></tr><tr><td>Female</td><td>1057 (58.4)</td><td>582 (63.1)</td><td>1639 (60.0)</td></tr><tr><td>Mean age (years), mean (SD)</td><td>39.6 (11.5)</td><td>38.8 (11.9)</td><td>39.3 (11.6)</td></tr><t... |
b273f72720870a9eb0f06491269b21fa671e00ba3d8418576c983ccdf969ce79.png | simple | <table><tr><td> </td><td>0–30 days post-implant</td><td>31–60 days post-implant</td><td>61–90 days post-implant</td></tr><tr><td>Pacemaker</td><td>35%</td><td>30%</td><td>67%</td></tr><tr><td>ICD</td><td>36%</td><td>42%</td><td>66%</td></tr><tr><td>CRT-D</td><td>34%</td><td>32%</td><td>77%</td></tr></... | <table><tr><td></td><td>0–30 days post-implant</td><td>31–60 days post-implant</td><td>61–90 days post-implant</td></tr></table> | <table><tr><td>Pacemaker</td><td>35%</td><td>30%</td><td>67%</td></tr><tr><td>ICD</td><td>36%</td><td>42%</td><td>66%</td></tr><tr><td>CRT-D</td><td>34%</td><td>32%</td><td>77%</td></tr></table> |
b0422b2ff0e87dbcecb96fcf18ff320ce2f3836079c9d1e8c84eb0f91bfa4a6e.png | complex | <table><tr><td colspan="3">Categorical variables</td><td colspan="3">Symptoms class of SCIN-total-score</td><td colspan="2">Univariate</td><td colspan="2">Multiple†</td></tr><tr><td colspan="2">GST genotype</td><td>Number (%)</td><td>No (0–5)</td><td>Moderate (6–9)</td><td>Severe (10–18)</td><td... | <table><tr><td colspan="3">Categorical variables</td><td colspan="3">Symptoms class of SCIN-total-score</td><td colspan="2">Univariate</td><td colspan="2">Multiple†</td></tr><tr><td colspan="2">GST genotype</td><td>Number (%)</td><td>No (0–5)</td><td>Moderate (6–9)</td><td>Severe (10–18)</td><td>P</td><td>OR (95% CI)</... | <table><tr><td colspan="3">Categorical variables</td><td colspan="3">Symptoms class of SCIN-total-score</td><td colspan="2">Univariate</td><td colspan="2">Multiple†</td></tr><tr><td>M1</td><td>+</td><td>134 (56.3)</td><td>79 (59.0)</td><td>35 (26.1)</td><td>20 (14.9)</td><td>0.947</td><td>0.98 (0.59–1.63)</td><td>0.166... |
8f7c0fcd53d9c85fe17f95cf121fdfc5b951951355c2c609309018083bbbf990.png | complex | <table><tr><td></td><td colspan="4">Unmatched cohorts</td><td colspan="3">Propensity-score matched cohorts</td></tr><tr><td>Complications</td><td>Human regular insulin <i>n</i> (%) </td><td>Rapid-acting Insulin Analogues <i>n</i> (%) </td><td>Adjusted HR<sup>a</sup> (95% CI)</td><td colspan="2">Human regular insulin <i... | <table><tr><td></td><td colspan="4">Unmatched cohorts</td><td colspan="3">Propensity-score matched cohorts</td></tr><tr><td>Complications</td><td>Human regular insulin n (%)</td><td>Rapid-acting Insulin Analogues n (%)</td><td>Adjusted HRa (95% CI)</td><td colspan="2">Human regular insulin n (%)</td><td>Rapid-acting In... | <table><tr><td>Cerebrovascular disease</td><td>75 (8.2)</td><td>38 (2.8)</td><td>0.55 (0.35-0.88)</td><td colspan="2">33 (5.8)</td><td>26 (4.6)</td><td>0.73 (0.44-1.20)</td></tr><tr><td>Microvascular</td><td>43 (4.7)</td><td>53 (3.9)</td><td>0.73 (0.45-1.20)</td><td colspan="2">27 (4.8)</td><td>26 (4.6)</td><td>0.89 (0... |
242cf30cfa41e9991f75c5dae55bf35e2f5989ae4e03bd4fc24efa147be68f29.png | complex | <table><tr><td> </td><td colspan="2">Males</td><td colspan="2">Females</td></tr><tr><td> </td><td>AOR</td><td>95% CI</td><td>AOR</td><td>95% CI</td></tr><tr><td>HIV Prevalence</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤ 0.37%</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>0.38-0.73%</... | <table><tr><td></td><td colspan="2">Males</td><td colspan="2">Females</td></tr><tr><td></td><td>AOR</td><td>95% CI</td><td>AOR</td><td>95% CI</td></tr><tr><td>HIV Prevalence</td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 0.37%</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>0.38-0.73%</td><td>1.1</... | <table><tr><td></td><td colspan="2">Males</td><td colspan="2">Females</td></tr><tr><td></td><td>AOR</td><td>95% CI</td><td>AOR</td><td>95% CI</td></tr><tr><td>24,001-32,600</td><td>0.63</td><td>0.40, 1.0</td><td>0.98</td><td>0.51, 1.9</td></tr><tr><td>32,601-44,200</td><td>0.92</td><td>0.62, 1.4</td><td>1.2</td><td>0.6... |
d21eee8130a8fec31d2d4339c69fac3f55473a40217e4f3325d1f1e081d25ec7.png | simple | <table><tr><td>Species</td><td>Number detected</td><td>(high; medium; low; no visible mould)</td></tr><tr><td><i>Epicoccum nigrum</i></td><td>15</td><td>(7,2,4,2)</td></tr><tr><td><i>Cladosporium cladosporioides</i></td><td>7</td><td>(3,3,1,0)</td></tr><tr><td><i>Aureobasidium pullulan</i></td><td>4</td><td>(1,1,2,0)</... | <table><tr><td>Species</td><td>Number detected</td></tr><tr><td>Epicoccum nigrum</td><td>15</td></tr><tr><td>Cladosporium cladosporioides</td><td>7</td></tr><tr><td>Aureobasidium pullulan</td><td>4</td></tr><tr><td>Cryptococcus flavescens</td><td>3</td></tr><tr><td>Alternaria alternata</td><td>2</td></tr><tr><td>Altern... | <table><tr><td>(high; medium; low; no visible mould)</td></tr><tr><td>(7,2,4,2)</td></tr><tr><td>(3,3,1,0)</td></tr><tr><td>(1,1,2,0)</td></tr><tr><td>(1,2,0,0)</td></tr><tr><td>(1,1,0,0)</td></tr><tr><td>(0,0,1,0)</td></tr><tr><td>(0,0,1,0)</td></tr><tr><td>(0,1,0,0)</td></tr><tr><td>(0,0,0,1)</td></tr><tr><td>(0,1,0,... |
797f0effba259b4e68a1f023b5e4f0b86ef6ec09e2688f1d0b603a17f1c06e7f.png | simple | <table><tr><td>Complications</td><td>Survivors (n = 46)</td><td>Non-survivors (n = 29)</td><td>P value<sup>a</sup></td></tr><tr><td>ARDS, n (%)</td><td>17 (37.6)</td><td>25 (86.2)</td><td><.001</td></tr><tr><td>Pneumonia, n (%)</td><td>41 (89.1)</td><td>27 (93.1)</td><td>.866</td></tr><tr><td>Arrhythmia, n (%)</td><... | <table><tr><td>Complications</td><td>Survivors (n = 46)</td><td>Non-survivors (n = 29)</td></tr><tr><td>ARDS, n (%)</td><td>17 (37.6)</td><td>25 (86.2)</td></tr><tr><td>Pneumonia, n (%)</td><td>41 (89.1)</td><td>27 (93.1)</td></tr><tr><td>Arrhythmia, n (%)</td><td>9 (19.6)</td><td>8 (27.6)</td></tr><tr><td>Alimentary t... | <table><tr><td>P valuea</td></tr><tr><td><.001</td></tr><tr><td>.866</td></tr><tr><td>.419</td></tr><tr><td>.066</td></tr><tr><td><.001</td></tr><tr><td>.390</td></tr><tr><td><.001</td></tr><tr><td>.949</td></tr><tr><td>.063</td></tr><tr><td>.013</td></tr></table> |
4365e1113c9bc0cf76d2599cb1705943e611441cb404884c11323694de9b80d7.png | complex | <table><tr><td colspan="2">ROSA item</td><td>Symptom domain</td><td>Factor</td><td>Loading</td></tr><tr><td>1</td><td>The patient is able to remember events from a long time ago.</td><td>Cognition</td><td>Factor 1</td><td>0.6857</td></tr><tr><td>2</td><td>The patient is able to remember events of the recent past.</td><... | <table><tr><td colspan="2">ROSA item</td></tr><tr><td>1</td><td>The patient is able to remember events from a long time ago.</td></tr><tr><td>2</td><td>The patient is able to remember events of the recent past.</td></tr><tr><td>3</td><td>The patient is able to plan and carry out complex procedures.</td></tr><tr><td>4</... | <table><tr><td>Symptom domain</td><td>Factor</td><td>Loading</td></tr><tr><td>Cognition</td><td>Factor 1</td><td>0.6857</td></tr><tr><td>Cognition</td><td></td><td>0.7448</td></tr><tr><td>Cognition</td><td></td><td>0.8526</td></tr><tr><td>Communication</td><td></td><td>0.7138</td></tr><tr><td>Communication</td><td></td... |
3825c1ca913079c36b99321c86fc65aa6b50dc7fd38a4644ea62c4a553cdee9b.png | complex | <table><tr><td></td><td>Hill and Upchurch7</td><td>Alkema <i>et al</i>2</td></tr><tr><td>Type</td><td>Prescriptive</td><td>Descriptive</td></tr><tr><td>Data</td><td>Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964<... | <table><tr><td></td><td>Hill and Upchurch7</td><td>Alkema et al2</td></tr><tr><td>Type</td><td>Prescriptive</td><td>Descriptive</td></tr><tr><td>Data</td><td>Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964</td><td... | <table><tr><td></td><td>Hill and Upchurch7</td><td>Alkema et al2</td></tr><tr><td>Assessment of gender bias</td><td>Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality</td><td>Countries with outlying sex ratios. Excess female mortality... |
04e2fc55ef09fa6496ca2868f1c0e157a7225a1872560c46ade7c1b1bd7f484f.png | complex | <table><tr><td>Domain name and number</td><td>ROC set No.</td><td>ROC variables</td><td>No. Obs</td><td>AUC</td><td>SENS</td><td>SPEC</td><td>PPV</td><td>NPV</td><td>% Risk of rejecting Ho</td><td>ROC <i>P</i> value</td><td>Odds ratio<sup>+</sup></td><td>Odds ratio <i>P</i> value</td><td>Accuracy</td></tr><tr><td rowsp... | <table><tr><td>Domain name and number</td><td>ROC set No.</td><td>ROC variables</td><td>No. Obs</td><td>AUC</td><td>SENS</td><td>SPEC</td><td>PPV</td><td>NPV</td><td>% Risk of rejecting Ho</td><td>ROC P value</td><td>Odds ratio+</td><td>Odds ratio P value</td><td>Accuracy</td></tr><tr><td rowspan="3">1. Visual</td><td>... | <table><tr><td>3. Catecholamine</td><td>9</td><td>High adrenaline</td><td>133</td><td>0.844</td><td>0.758</td><td>0.821</td><td>0.019</td><td>0.999</td><td>0.01</td><td><0.0001</td><td>14.32</td><td><0.0001</td><td>0.7895</td></tr><tr><td>4. Oxidative stress</td><td>10</td><td>High (HPL/creatinine)a (oxidative stress d... |
bb57ff60a2c624b34fc1cbcd8535a43a16bbd3f6f0a647380e811cc4f48c55a2.png | simple | <table><tr><td>Chemokine</td><td>Forward primer</td><td>Reverse primer</td><td>Product size (bp)</td></tr><tr><td>CCL-chr25s</td><td>5'-TTCTGCTGTTTTTGGTGTTCA</td><td>5'-GCTTTATCCAGTCCTCATCTGG</td><td>216</td></tr><tr><td>CCL-chr24a</td><td>5'-TACTTCTCAGCTTCCTTGTGGAGA</td><td>5'-CTCATCGTCTTCGTCTTCATTGTT</td><td>250</td>... | <table><tr><td>Chemokine</td><td>Forward primer</td><td>Reverse primer</td><td>Product size (bp)</td></tr><tr><td>CCL-chr25s</td><td>5'-TTCTGCTGTTTTTGGTGTTCA</td><td>5'-GCTTTATCCAGTCCTCATCTGG</td><td>216</td></tr><tr><td>CCL-chr24a</td><td>5'-TACTTCTCAGCTTCCTTGTGGAGA</td><td>5'-CTCATCGTCTTCGTCTTCATTGTT</td><td>250</td>... | <table><tr><td>CXCL-chr5c</td><td>5'-AAGTGCGTGCCTGATAAACC</td><td>5'-CACATCAACTGCCTGAATGG</td><td>229</td></tr><tr><td>CXCL-chr5d</td><td>5'-TGTTACTGCTCTGCTTCTTGTCA</td><td>5'-CATCGTTTTCCAGCTCCATT</td><td>204</td></tr><tr><td>CXCL-chr1c</td><td>5'-TACGTCCAGCAGGGAGAAGT</td><td>5'-CCCTGCTGTTTTTGTGGATT</td><td>218</td></t... |
1a4f944a7f32d980972b2b639b4015c0eabc555da90f578f207c0d782cc27b0c.png | complex | <table><tr><td>Gender</td><td colspan="2">Male</td></tr><tr><td>Age</td><td colspan="2">10 y</td></tr><tr><td>Diagnosis</td><td colspan="2">Oppositional defiant disorder</td></tr><tr><td>Intellligence quotient (IQ)</td><td colspan="2">59</td></tr><tr><td>NCBRF total score</td><td></td><td></td></tr><tr><td> Baseline</t... | <table><tr><td>Gender</td><td colspan="2">Male</td></tr><tr><td>Age</td><td colspan="2">10 y</td></tr><tr><td>Diagnosis</td><td colspan="2">Oppositional defiant disorder</td></tr><tr><td>Intellligence quotient (IQ)</td><td colspan="2">59</td></tr></table> | <table><tr><td>NCBRF total score</td><td></td><td></td></tr><tr><td>Baseline</td><td colspan="2">33</td></tr><tr><td>Endpoint</td><td colspan="2">31</td></tr><tr><td>Time point</td><td>Risperidone dose (mg/day)</td><td>Dyskinesia score*</td></tr><tr><td>Baseline</td><td>0.000</td><td>3</td></tr><tr><td>Week 1</td><td>0... |
ad00f63b01ab13e483569ceb153c455474ad5006f486b5ebe9f3ff619a9ac7d4.png | simple | <table><tr><td></td><td>Screening</td><td>Pretreatment</td><td>Discharge</td><td>End of Intervention</td><td>Follow-up</td></tr><tr><td>Study visits</td><td></td><td>T0</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td>Written informed consent</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Screening que... | <table><tr><td></td><td>Screening</td><td>Pretreatment</td><td>Discharge</td><td>End of Intervention</td><td>Follow-up</td></tr><tr><td>Study visits</td><td></td><td>T0</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td>Written informed consent</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Screening que... | <table><tr><td>GAD-7</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>PHQ-9</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>RSE</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>EUROHIS-QOL 8</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>DAS</td><td>X</td><td>X</td><td></td><td>X</td></tr... |
25dde062e7f93af4555fda3db5c415a90fcfacc51556fa70f4a0b552f1eb354e.png | complex | <table><tr><td rowspan="2">Goal</td><td rowspan="2">I have set this goal (<i>N</i>)</td><td rowspan="2">Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)</td><td colspan="3">I will continue to make these changes after the intervention</td></tr><tr><td>Very likely (%)</td><td>Likely (%)</td><td... | <table><tr><td rowspan="2">Goal</td><td rowspan="2">I have set this goal (N)</td><td rowspan="2">Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)</td><td>I will continue to make these changes after the intervention</td></tr><tr><td>Very likely (%)</td></tr><tr><td>Improving diet</td><td>346</... | <table><tr><td colspan="2">I will continue to make these changes after the intervention</td></tr><tr><td>Likely (%)</td><td>Not sure (%)</td></tr><tr><td>15</td><td>2</td></tr><tr><td>32</td><td>1</td></tr><tr><td>18</td><td>–</td></tr><tr><td>34</td><td>10</td></tr></table> |
3feac42582fc27ac74384718b9fbeafd304bf75628d19ee29cec85efa9e3bf13.png | simple | <table><tr><td>Isoform</td><td>Substrate</td><td>Metabolite</td><td>Ranges of substrate concentrations in the incubations, μM</td><td>Fluorescence detection excitation/emission</td></tr><tr><td>CYP1A</td><td>ER</td><td>resorufin</td><td>0.1–12.0</td><td>560/586 nm</td></tr><tr><td>CYP2A</td><td>coumarin</td>... | <table><tr><td>Isoform</td><td>Substrate</td><td>Metabolite</td><td>Ranges of substrate concentrations in the incubations, μM</td><td>Fluorescence detection excitation/emission</td></tr><tr><td>CYP1A</td><td>ER</td><td>resorufin</td><td>0.1–12.0</td><td>560/586 nm</td></tr></table> | <table><tr><td>CYP2A</td><td>coumarin</td><td>hydroxycoumarin</td><td>2.5–300.0</td><td>338/458 nm</td></tr><tr><td>CYP3A</td><td>BFC</td><td>HFC</td><td>0.4–120.0</td><td>410/538 nm</td></tr></table> |
3fc81942f717d9bb8dc56175eef9044b2651a3669868587e5eb6785c6e7a376c.png | complex | <table><tr><td>SNPs</td><td>No. of every SNP type</td><td>Caused by</td><td>Total No. of transition and transversion</td></tr><tr><td>A/G</td><td>28769</td><td rowspan="2">Transition</td><td rowspan="2">53208</td></tr><tr><td>C/T</td><td>24439</td></tr><tr><td>A/C</td><td>6832</td><td rowspan="4">Transversion</td><td r... | <table><tr><td>SNPs</td><td>No. of every SNP type</td><td>Caused by</td><td>Total No. of transition and transversion</td></tr><tr><td>A/G</td><td>28769</td><td rowspan="2">Transition</td><td rowspan="2">53208</td></tr><tr><td>C/T</td><td>24439</td></tr><tr><td>A/C</td><td>6832</td><td rowspan="2">Transversio</td><td ro... | <table><tr><td>SNPs</td><td>No. of every SNP type</td><td>Caused by</td><td>Total No. of transition and transversion</td></tr><tr><td></td><td>2016</td><td rowspan="3">n</td><td rowspan="3">67</td></tr><tr><td>A/T</td><td>4315</td></tr><tr><td>G/C</td><td>7504</td></tr></table> |
3643a862c28b44139ae096ec26c766f3ef21ec85ee067d78f30dc287ea94ee78.png | simple | <table><tr><td>Term</td><td>Definition</td></tr><tr><td>SP-trEMBL</td><td>Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.</td></tr><tr><td>Integr8_263</td><td>Sequence dataset containing 913,094 sequences from 263 completed genomes listed ... | <table><tr><td>Term</td></tr><tr><td>SP-trEMBL</td></tr><tr><td>Integr8_263</td></tr><tr><td>Pfam_struc</td></tr><tr><td>NewFam</td></tr></table> | <table><tr><td>Definition</td></tr><tr><td>Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.</td></tr><tr><td>Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database.</td></tr><tr><td>Pf... |
b8163d45e8a1a6872fc8d05a543655ed4ca02a8c3007bd50787b5ceca8bc4c99.png | simple | <table><tr><td></td><td>EDA group (n = 68)</td><td>Opioid group (n = 98)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>59.3 ± 16.0</td><td>59.9 ± 15.3</td><td>n.s.</td></tr><tr><td>Male gender (%)</td><td>58.8</td><td>66.3</td><td>n.s.</td></tr><tr><td>Hospital stay (days)</td><td>9.8 ± 5.7</td><t... | <table><tr><td></td><td>EDA group (n = 68)</td><td>Opioid group (n = 98)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>59.3 ± 16.0</td><td>59.9 ± 15.3</td><td>n.s.</td></tr><tr><td>Male gender (%)</td><td>58.8</td><td>66.3</td><td>n.s.</td></tr><tr><td>Hospital stay (days)</td><td>9.8 ± 5.7</td><td>11.1 ± 9.4</t... | <table><tr><td>Time to first dejection (days)</td><td>3.5 ± 1.8</td><td>3.9 ± 2.2</td><td>n.s.</td></tr><tr><td>EDA duration (days)</td><td>4.5 ± 2.0</td><td>-</td><td></td></tr></table> |
000221630ba33f9118f2671a715d6962e08d6b76a5a0c77a9fe26c291df763b0.png | complex | <table><tr><td></td><td colspan="2">PD-L1 Expression</td><td><i>*P</i> value</td></tr><tr><td></td><td>+</td><td>-</td><td></td></tr><tr><td>E-Cadherin</td><td></td><td></td><td></td></tr><tr><td>Down-regulated (≤70 %)</td><td>9 (47)<sup>a</sup></td><td>10 (53)</td><td>0.039</td></tr><tr><td>Positive (> 70 %)<... | <table><tr><td></td><td colspan="2">PD-L1 Expression</td><td>*P value</td></tr><tr><td></td><td>+</td><td>-</td><td></td></tr><tr><td>E-Cadherin</td><td></td><td></td><td></td></tr><tr><td>Down-regulated (≤70 %)</td><td>9 (47)a</td><td>10 (53)</td><td>0.039</td></tr><tr><td>Positive (> 70 %)</td><td>10 (21)</td><td>38 ... | <table><tr><td>Negative (<5 %)</td><td>9 (19)</td><td>39 (81)</td><td></td></tr><tr><td>E-Cadherin-down/Vimentin-up</td><td></td><td></td><td></td></tr><tr><td>Present</td><td>6 (75)</td><td>2(25)</td><td>0.005</td></tr><tr><td>Absent</td><td>13 (22)</td><td>46 (78)</td><td></td></tr></table> |
aaee931a2962f3d966b27880c7684593d5a03d18218a71a870277745b3cff977.png | complex | <table><tr><td>Reference</td><td colspan="2">Numbers studied</td><td>Type of controls</td><td>Susceptibility</td><td>Severity</td><td>Ethnicity</td></tr><tr><td></td><td>Cancer</td><td>Controls</td><td></td><td></td><td></td><td></td></tr><tr><td>Hefler LA et al, 2005 [58]</td><td>269</td><td>227</td><td>Women visiting... | <table><tr><td>Reference</td><td colspan="2">Numbers studied</td><td>Type of controls</td><td>Susceptibility</td><td>Severity</td><td>Ethnicity</td></tr><tr><td></td><td>Cancer</td><td>Controls</td><td></td><td></td><td></td><td></td></tr><tr><td>Hefler LA et al, 2005 [58]</td><td>269</td><td>227</td><td>Women visiting... | <table><tr><td>Reference</td><td colspan="2">Numbers studied</td><td>Type of controls</td><td>Susceptibility</td><td>Severity</td><td>Ethnicity</td></tr><tr><td></td><td>Cancer</td><td>Controls</td><td></td><td></td><td></td><td></td></tr><tr><td>Our study</td><td>691</td><td>420</td><td>Women with normal mammograms fr... |
ab8fda155873ef049ed4f29a6a4707c13f1b03dbd083de3fba9590d487a23146.png | complex | <table><tr><td></td><td colspan="4">Region of interest (ROI)</td></tr><tr><td>Period (months)</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td colspan="5">Monoblock</td></tr><tr><td> 0–12</td><td>–0.16 (–0.22 to –0.10)</td><td>–0.16 (–0.24 to –0.08)</td><td>–0.09 ... | <table><tr><td></td><td colspan="3">Region of interest (ROI)</td></tr><tr><td>Period (months)</td><td>1</td><td>2</td><td>3</td></tr><tr><td colspan="4">Monoblock</td></tr><tr><td>0–12</td><td>–0.16 (–0.22 to –0.10)</td><td>–0.16 (–0.24 to –0.08)</td><td>–0.09 (–0.15 to –0.03)</td></tr><tr><td>12–24</td><td>–0.04 (–0.1... | <table><tr><td>Region of interest (ROI)</td></tr><tr><td>4</td></tr><tr><td>Monoblock</td></tr><tr><td>–0.07 (–0.11 to –0.04)</td></tr><tr><td>0.00 (–0.03 to 0.03)</td></tr><tr><td>–0.08 (–0.12 to 0.04</td></tr><tr><td>Trilogy</td></tr><tr><td>–0.10 (–0.24 to 0.04)</td></tr><tr><td>–0.01 (–0.08 to 0.07)</td></tr><tr><t... |
d6fc0ba92d229512af81bbbf1091cfbb78caff6d499f57d6483b64c424a41bb6.png | complex | <table><tr><td></td><td colspan="2">Group A</td><td colspan="2">Group B</td><td></td></tr><tr><td></td><td colspan="2">6–8 years (<i>n</i> = 11)</td><td colspan="2">9–10 years (<i>n</i> = 17)</td><td rowspan="2"><i>P</i> value</td></tr><tr><td></td><td>median</td><td>range</td><td>median</td><td>range</td><... | <table><tr><td></td><td colspan="2">Group A</td><td colspan="2">Group B</td><td></td></tr></table> | <table><tr><td></td><td colspan="2">6–8 years (n = 11)</td><td colspan="2">9–10 years (n = 17)</td><td rowspan="2">P value</td></tr><tr><td></td><td>median</td><td>range</td><td>median</td><td>range</td></tr><tr><td>Pelvis X</td><td>18.2</td><td>12.5–24.9</td><td>19.5</td><td>7.0–28.6</td><td>0.495</td></tr><tr><td>Pel... |
a838176a8382dfeaef0b6b7220b7a321746b2fe1888393b97f2de964deb0e54d.png | simple | <table><tr><td>Simulation Results</td><td>Yeast 5</td><td>Yeast 6</td></tr><tr><td>Auxotroph-inducing genes</td><td>92</td><td>93</td></tr><tr><td>Correct auxotrophy predictions</td><td>57</td><td>64</td></tr><tr><td>Mutant incorrectly predicted to be viable in minimal medium</td><td>32</td><td>26</td></tr><tr><td>Muta... | <table><tr><td>Simulation Results</td><td>Yeast 5</td><td>Yeast 6</td></tr><tr><td>Auxotroph-inducing genes</td><td>92</td><td>93</td></tr><tr><td>Correct a</td><td></td><td></td></tr></table> | <table><tr><td>uxotrophy predictions</td><td>57</td><td>64</td></tr><tr><td>Mutant incorrectly predicted to be viable in minimal medium</td><td>32</td><td>26</td></tr><tr><td>Mutant incorrectly predicted to be inviable in supplemented medium</td><td>3</td><td>3</td></tr></table> |
6880acc786d2989f4499d641db3f010f71c8f6a3f66724cfb58c3b4ccf2d2890.png | complex | <table><tr><td></td><td colspan="3">Group C</td><td colspan="3">Group B</td></tr><tr><td>Subgroups</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 7)</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 4)</td></tr><tr>... | <table><tr><td></td><td colspan="3">Group C</td><td colspan="3">Group B</td></tr><tr><td>Subgroups</td><td>Normotensive(n = 41)</td><td>Treated HT(n = 7)</td><td>Untreated HT(n = 7)</td><td>Normotensive(n = 41)</td><td>Treated HT(n = 7)</td><td>Untreated HT(n = 4)</td></tr><tr><td>Additional Propofol</td><td>22 (55 %)<... | <table><tr><td></td><td colspan="3">Group C</td><td colspan="3">Group B</td></tr><tr><td>Subgroups</td><td>Normotensive(n = 41)</td><td>Treated HT(n = 7)</td><td>Untreated HT(n = 7)</td><td>Normotensive(n = 41)</td><td>Treated HT(n = 7)</td><td>Untreated HT(n = 4)</td></tr><tr><td>SBP < 70 mmHg</td><td>8 (20 %)</td><td... |
6288801ae9ebc7debebf85601cc88d039f643d96ba49f1c42431d9b5977ed83a.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">Univariate<sup>a</sup></td><td colspan="2">Multivariate<sup>a</sup></td></tr><tr><td>HR (95 % CI)</td><td><i>P</i> value</td><td>HR (95 % CI)</td><td><i>P</i> value</td></tr><tr><td colspan="5">Baseline characteristics</td></tr><tr><td>Age <70 y (vs. ≥70... | <table><tr><td rowspan="2">Variables</td><td colspan="2">Univariatea</td><td colspan="2">Multivariatea</td></tr><tr><td>HR (95 % CI)</td><td>P value</td><td>HR (95 % CI)</td><td>P value</td></tr><tr><td colspan="5">Baseline characteristics</td></tr><tr><td>Age <70 y (vs. ≥70 y)</td><td>0.749 (0.343–1.429)</td><td>0.380... | <table><tr><td rowspan="2">Variables</td><td colspan="2">Univariatea</td><td colspan="2">Multivariatea</td></tr><tr><td>HR (95 % CI)</td><td>P value</td><td>HR (95 % CI)</td><td>P value</td></tr><tr><td>≥50 mm)</td><td>0.777 (0.412–1.466)</td><td></td><td></td><td></td></tr><tr><td>Previous curative therapy: Yes (vs. N... |
236061c79ffbc38b328ed065c3528f3d28410135e251d379b3bbf6da7e0e9136.png | simple | <table><tr><td>Subgroups</td><td>n</td><td>Cases of the grade of tracheal intubation conditions (1/2/3/4)</td><td>Cases of the anaphylaxis score (0/1/2/3)</td><td>Duration of surgery (min)</td></tr><tr><td>Group 1</td><td>39</td><td>29/10/0/0</td><td>32/7/0/0</td><td>69 ± 34</td></tr><tr><td>Group 2</td><td>37</td... | <table><tr><td>Subgroups</td><td>n</td><td>Cases of the grade of tracheal intubation conditions (1/2/3/4)</td><td>Cases of the anaphylaxis score (0/1/2/3)</td><td>Duration of surgery (min)</td></tr><tr><td>Group 1</td><td>39</td><td>29/10/0/0</td><td>32/7/0/0</td><td>69 ± 34</td></tr></table> | <table><tr><td>Subgroups</td><td>n</td><td>Cases of the grade of tracheal intubation conditions (1/2/3/4)</td><td>Cases of the anaphylaxis score (0/1/2/3)</td><td>Duration of surgery (min)</td></tr><tr><td>Group 2</td><td>37</td><td>29/8/0/0</td><td>35/2/0/0</td><td>75 ± 40</td></tr><tr><td>Group 3</td><td>39</td><td>3... |
4cb8ec2b1f3a483911f22758fff18c2b04f2ee66d5fed2eb550b3c1092a987e4.png | simple | <table><tr><td>Demographic Characteristics</td><td>TOTAL</td><td>%</td></tr><tr><td>Female</td><td>15</td><td>75%</td></tr><tr><td>Race</td><td></td><td></td></tr><tr><td> White</td><td>15</td><td>75%</td></tr><tr><td> Black</td><td>4</td><td>20%</td></tr><tr><td> Asian</td><td>1</td><td>5%</td></tr><tr><td>Age</td><td... | <table><tr><td>Demographic Characteristics</td><td>TOTAL</td><td>%</td></tr><tr><td>Female</td><td>15</td><td>75%</td></tr><tr><td>Race</td><td></td><td></td></tr><tr><td>White</td><td>15</td><td>75%</td></tr><tr><td>Black</td><td>4</td><td>20%</td></tr><tr><td>Asian</td><td>1</td><td>5%</td></tr><tr><td>Age</td><td></... | <table><tr><td>Demographic Characteristics</td><td>TOTAL</td><td>%</td></tr><tr><td>Home</td><td>9</td><td>45%</td></tr><tr><td>Library</td><td>4</td><td>20%</td></tr><tr><td>Multiple sites</td><td>5</td><td>25%</td></tr></table> |
f069b52cc2fe1db61c77941dc1bfb5b21d14bbd821dac229479c2a34dd96c4f5.png | complex | <table><tr><td></td><td></td><td colspan="2">Using allopurinol</td></tr><tr><td>Factor</td><td>Frequency (%)</td><td>No (%)</td><td>Yes (%)</td></tr><tr><td>Age Mean (SD)</td><td>65.6 (12.5)</td><td>65.1 (13.4)</td><td>65.9 (11.6)</td></tr><tr><td>Gender (Male %)</td><td>990 (83.6)</td><td>390 (79.6)</td><td>544 (86.4)... | <table><tr><td></td><td></td><td colspan="2">Using allopurinol</td></tr><tr><td>Factor</td><td>Frequency (%)</td><td>No (%)</td><td>Yes (%)</td></tr><tr><td>Age Mean (SD)</td><td>65.6 (12.5)</td><td>65.1 (13.4)</td><td>65.9 (11.6)</td></tr><tr><td>Gender (Male %)</td><td>990 (83.6)</td><td>390 (79.6)</td><td>544 (86.4)... | <table><tr><td>Daily</td><td>273 (23.4)</td><td>108 (22.5)</td><td>149 (23.8)</td></tr><tr><td colspan="4">Body Mass Index</td></tr><tr><td>Normal (<25 kg/m2)</td><td>371 (31.3)</td><td>168 (34.3)</td><td>178 (28.2)</td></tr><tr><td>Overweight/obese (≥25 kg/m2)</td><td>813 (68.7)</td><td>322 (65.7)</td><td>452 (71.8)</... |
f28b1745581ddc6333f0b06cdc9c279e65fdf656e31ad893b6f7fa3ad524a594.png | simple | <table><tr><td>MiR</td><td>Parametric p-value</td><td>FDR</td><td>Permutation p-value</td><td>Geom mean of intensities in class 1</td><td>Geom mean of intensities in class 2</td><td>Geom mean of intensities in class 3</td><td>Geom mean of intensities in class 4</td></tr><tr><td>hsa-miR-204-4373094</td><td>0.00004</td><... | <table><tr><td>MiR</td><td>Parametric p-value</td><td>FDR</td><td>Permutation p-value</td><td>Geom mean of intensities in class 1</td><td>Geom mean of intensities in class 2</td><td>Geom mean of intensities in class 3</td><td>Geom mean of intensities in class 4</td></tr><tr><td>hsa-miR-204-4373094</td><td>0.00004</td><... | <table><tr><td>MiR</td><td>Parametric p-value</td><td>FDR</td><td>Permutation p-value</td><td>Geom mean of intensities in class 1</td><td>Geom mean of intensities in class 2</td><td>Geom mean of intensities in class 3</td><td>Geom mean of intensities in class 4</td></tr><tr><td>hsa-miR-30aSTAR-4373062</td><td>0.00035</... |
b1aeac26679b03209d72b8bdc3d7c7e4de71dcc23f8b542435b2d88beaa48f64.png | simple | <table><tr><td>Test</td><td>TAA/TAD (%)</td><td>Control (%)</td><td>P-value</td></tr><tr><td>White Blood Cell</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>93 (70)</td><td>103 (77)</td><td>0.29</td></tr><tr><td>Low (<3 million cells/mcL)</td><td>8 (6)</td><td>9 (7)</td><td>1</td></tr><tr><td>High (&g... | <table><tr><td>Test</td><td>TAA/TAD (%)</td><td>Control (%)</td><td>P-value</td></tr><tr><td>White Blood Cell</td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>93 (70)</td><td>103 (77)</td><td>0.29</td></tr><tr><td>Low (<3 million cells/mcL)</td><td>8 (6)</td><td>9 (7)</td><td>1</td></tr><tr><td>High (>12 mill... | <table><tr><td>Elevated (> 250 ng/ml)</td><td>4 (80)</td><td>1 (13)</td><td>0.06</td></tr><tr><td>Troponin</td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>53 (82)</td><td>80 (66)</td><td>0.04</td></tr><tr><td>Elevated (>0.3 ng/mL)</td><td>12 (18)</td><td>41 (34)</td><td>0.04*</td></tr></table> |
c9d894ccb57fd873bb5b5b4cf479024ea4f7715feee7e22eda8b6e3c4ec0cf8c.png | simple | <table><tr><td></td><td>Count</td><td>%</td></tr><tr><td>He/she used to work but is currently unemployed</td><td>0</td><td>0.00</td></tr><tr><td>He/she never worked and neither does now</td><td>0</td><td>0.00</td></tr><tr><td>Clerk (civil or private)</td><td>338</td><td>63.41</td></tr><tr><td>Free professional (tradesm... | <table><tr><td></td><td>Count</td><td>%</td></tr><tr><td>He/she used to work but is currently unemployed</td><td>0</td><td>0.00</td></tr><tr><td>He/she never worked and neither does now</td><td>0</td><td>0.00</td></tr><tr><td>Clerk (civil or private)</td><td>338</td><td>63.41</td></tr><tr><td>Free professional (tradesm... | <table><tr><td></td><td>Count</td><td>%</td></tr><tr><td>Student (college or university)</td><td>12</td><td>2.25</td></tr><tr><td>Blue collar worker (construction worker, farmer)</td><td>26</td><td>4.88</td></tr><tr><td>Housewife</td><td>20</td><td>3.75</td></tr><tr><td>Total</td><td>533</td><td>100.00</td></tr></table... |
8f9e8870f4cd5f6bb1f4e98c06cfd46e45330158180592ad0baaba6edecb1f80.png | simple | <table><tr><td>Variables</td><td>N (%)</td><td>Prevalence of Internet use (%)<sup>a</sup></td><td>Total scores<sup>b</sup></td><td>Prevalence of AIA (%)<sup>c,d</sup></td></tr><tr><td>Paternal education (missing 23)</td><td> </td><td><i>p</i> <0.001</td><td><i>p</i> <0.001</td><td><i>p =</i>0.01</td></tr><tr><td>... | <table><tr><td>Variables</td><td>N (%)</td><td>Prevalence of Internet use (%)a</td><td>Total scoresb</td><td>Prevalence of AIA (%)c,d</td></tr><tr><td>Paternal education (missing 23)</td><td></td><td>p <0.001</td><td>p <0.001</td><td>p =0.01</td></tr><tr><td>Illiteracy and elementary</td><td>101 (2.0%)</td><td>84.2% (8... | <table><tr><td>Variables</td><td>N (%)</td><td>Prevalence of Internet use (%)a</td><td>Total scoresb</td><td>Prevalence of AIA (%)c,d</td></tr><tr><td>Nuclear family</td><td>3380 (66.0%)</td><td>93.5% (3158/3380)</td><td>118.9 ± 41.2</td><td>8.5% (288/3380)</td></tr><tr><td>Three-generation family</td><td>1069 (20.9%)<... |
f2d9d750017e9a50421c8de909d705203eb8fa763ddb698ae3312a40e8f664ef.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">Mean ± SD before and after treatment with</td></tr><tr><td>PZQ</td><td>ARA</td><td>PZQ + ARA</td></tr><tr><td>Children</td><td>84</td><td>88</td><td>83</td></tr><tr><td colspan="4">Parameter</td></tr><tr><td colspan="4"> PT (seconds)</td></tr><tr><td>Before</td><td>1... | <table><tr><td rowspan="2"></td></tr><tr></tr><tr><td>Children</td></tr><tr><td>Parameter</td></tr><tr><td>PT (seconds)</td></tr><tr><td>Before</td></tr><tr><td>After</td></tr><tr><td>P value</td></tr><tr><td>CT (seconds)</td></tr><tr><td>Before</td></tr><tr><td>After</td></tr><tr><td>P value</td></tr><tr><td>PT concen... | <table><tr><td colspan="3">Mean ± SD before and after treatment with</td></tr><tr><td>PZQ</td><td>ARA</td><td>PZQ + ARA</td></tr><tr><td>84</td><td>88</td><td>83</td></tr><tr><td colspan="3">Parameter</td></tr><tr><td colspan="3">PT (seconds)</td></tr><tr><td>14.43 ± 0.96</td><td>14.25 ± 0.75</td><td>14.31 ± 0.71</td><... |
9e32a35158626c24a7f9c17a80c360ee7a866599257474c00580b028bb472b28.png | complex | <table><tr><td></td><td colspan="2">PLK1</td><td colspan="2">PAK4</td><td colspan="2">PAK5</td><td colspan="2">PAK6</td></tr><tr><td></td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td></tr><tr><td>PLK1</td><td>0.000</td><td>100</td><td>0.981</td><td>39.688</td><td>0.976... | <table><tr><td></td><td colspan="2">PLK1</td><td colspan="2">PAK4</td><td colspan="2">PAK5</td><td colspan="2">PAK6</td></tr><tr><td></td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td></tr><tr><td>PLK1</td><td>0.000</td><td>100</td><td>0.981</td><td>39.688</td><td>0.976... | <table><tr><td>5</td><td>976</td><td>813</td><td>0.681</td><td>898</td><td>00</td><td>00</td><td>.870</td><td>58.045</td></tr><tr><td>PAK6</td><td>0.969</td><td>39.264</td><td>0.845</td><td>63.776</td><td>0.870</td><td>58.045</td><td>0.000</td><td>100</td></tr></table> |
1aa1585031b997a442f81191f82dee78094a186a444d500fabbf77630663a34e.png | simple | <table><tr><td> </td><td>Hazard ratio</td><td>95% confidence interval</td><td><i>p</i> value</td></tr><tr><td>Mean age<sup><i>∗</i></sup></td><td>1.026</td><td>1.013–1.040</td><td><0.001</td></tr><tr><td>Country of birth, Nordic country</td><td>1.446</td><td>0.980–2.135</td><td>0.063</td></tr><tr><... | <table><tr><td></td><td>Hazard ratio</td><td>95% confidence interval</td><td>p value</td></tr><tr><td>Mean age∗</td><td>1.026</td><td>1.013–1.040</td><td><0.001</td></tr><tr><td>Country of birth, Nordic country</td><td>1.446</td><td>0.980–2.135</td><td>0.063</td></tr><tr><td>Chronic physical disease</td><td>1.025</td><... | <table><tr><td></td><td>Hazard ratio</td><td>95% confidence interval</td><td>p value</td></tr><tr><td>Heroin∗</td><td>1.737</td><td>1.261–2.393</td><td>0.001</td></tr><tr><td>Other opioids</td><td>0.938</td><td>0.655–1.345</td><td>0.729</td></tr><tr><td>Sedatives∗</td><td>1.404</td><td>1.026-1.923</td><td>0.034</td></t... |
7123cf308f247dbde38f3b1d735d14cf94b74128a654bc07ec8a12bbc61bb6ef.png | simple | <table><tr><td>Cardiometabolic disease outcome</td><td>Amount quintile 1</td><td>Amount quintile 2</td><td>Amount quintile 3</td><td>Amount quintile 4</td><td>Amount quintile 5</td><td><i>P</i>-trend</td></tr><tr><td>Odds ratio (95% CI)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Cardiometab... | <table><tr><td>Cardiometabolic disease outcome</td><td>Amount quintile 1</td><td>Amount quintile 2</td><td>Amount quintile 3</td><td>Amount quintile 4</td><td>Amount quintile 5</td><td>P-trend</td></tr><tr><td>Odds ratio (95% CI)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td>Cardiometabolic</td><td>Referent</td><td>0.88 (0.76–1.03)</td><td>1.04 (0.88–1.21)</td><td>0.94 (0.82–1.06)</td><td>0.95 (0.82–1.11)</td><td>0.805</td></tr><tr><td>Cardiovascular</td><td>Referent</td><td>0.79 (0.65–0.97)</td><td>0.97 (0.78–1.21)</td><td>0.81 (0.67–0.99)</td><td>0.79 (0.64–0.97)</td><td>0... |
2467cea2ebd88e34eb0b80fac644b764a51dd512bc25d7e8aafe47c50838b15d.png | simple | <table><tr><td>Cluster ID</td><td>No. of sequences</td><td>Percentage of effective siRNAs (%)</td></tr><tr><td>C1</td><td>134</td><td>94</td></tr><tr><td>C2</td><td>150</td><td>70.7</td></tr><tr><td>C3</td><td>125</td><td>70.4</td></tr><tr><td>C4</td><td>147</td><td>61.9</td></tr><tr><td>C5</td><td>141</td><td>43.3</td... | <table><tr><td>Cluster ID</td><td>No. of sequences</td><td>Percentage of effective siRNAs (%)</td></tr><tr><td>C1</td><td>1</td><td>94</td></tr></table> | <table><tr><td></td><td>34</td><td></td></tr><tr><td>C2</td><td>150</td><td>70.7</td></tr><tr><td>C3</td><td>125</td><td>70.4</td></tr><tr><td>C4</td><td>147</td><td>61.9</td></tr><tr><td>C5</td><td>141</td><td>43.3</td></tr><tr><td>C6</td><td>158</td><td>32.3</td></tr><tr><td>C7</td><td>143</td><td>27.1</td></tr><tr><... |
5b2605e0acac303ad25e730289eab19d7608853a166eca1d036b6676f3aed78c.png | simple | <table><tr><td></td><td>No. Patients (%)</td><td>Methylation (%)</td><td><i>P</i></td></tr><tr><td>All patients </td><td>50 (100)</td><td>31( 62)</td><td></td></tr><tr><td> Male</td><td>42 ( 84)</td><td>27 (64)</td><td></td></tr><tr><td> Female</td><td>8 (16)</td><td>4 (50)</td><td>0.450</td></tr><tr><td>Site</td><td><... | <table><tr><td></td><td>No. Patients (%)</td><td>Methylation (%)</td><td>P</td></tr><tr><td>All patients</td><td>50 (100)</td><td>31( 62)</td><td></td></tr></table> | <table><tr><td>Male</td><td>42 ( 84)</td><td>27 (64)</td><td></td></tr><tr><td>Female</td><td>8 (16)</td><td>4 (50)</td><td>0.450</td></tr><tr><td>Site</td><td></td><td></td><td></td></tr><tr><td>Oral Cavity</td><td>22 (44)</td><td>13 (59)</td><td></td></tr><tr><td>Oropharynx</td><td>5 (10)</td><td>4 (80)</td><td></td>... |
f95e31829130f0eb250596c789b2f739fff2d6943061f70339fe68f6dc09632c.png | simple | <table><tr><td>Method</td><td>Resnik</td><td>Relevance</td><td>Wang</td><td>NETSIM</td><td>NETSIM2</td></tr><tr><td>25%</td><td>0.07</td><td>0.15</td><td>0.17</td><td>0.12</td><td>0.002</td></tr><tr><td>50%</td><td>0.17</td><td>0.43</td><td>0.40</td><td>0.47</td><td>1.94</td></tr><tr><td>75%</td><td>0.42</td><td>1.03</... | <table><tr><td>Method</td><td>Resnik</td><td>Relevance</td><td>Wang</td><td>NETSIM</td><td>NETSIM2</td></tr><tr><td>25%</td><td>0.07</td><td>0.15</td><td>0.17</td><td>0.12</td><td>0.002</td></tr><tr><td>50%</td><td>0.17</td><td>0.43</td><td>0.40</td><td>0.47</td><td>1.94</td></tr></table> | <table><tr><td>Method</td><td>Resnik</td><td>Relevance</td><td>Wang</td><td>NETSIM</td><td>NETSIM2</td></tr><tr><td>75%</td><td>0.42</td><td>1.03</td><td>0.91</td><td>1.19</td><td>3.75</td></tr></table> |
5323677ce9e9a78d3679fdf3b1a9728be1da2c38afc4ee09e1eb4ea06dc87c1b.png | complex | <table><tr><td> </td><td colspan="3">Without DM (n = 334)</td><td colspan="3">With DM (n = 122)</td></tr><tr><td>Characteristics</td><td>VAT T1 (n = 111)</td><td>VAT T2 (n = 112)</td><td>VAT T3 (n = 111)</td><td>VAT T1 (n = 40)</td><td>VAT T2 (n = 41)</td><td>VAT T3 (n = 41)</td></tr><tr><td>Calcified plaque</td><td>1.... | <table><tr><td></td><td colspan="3">Without DM (n = 334)</td><td colspan="3">With DM (n = 122)</td></tr><tr><td>Characteristics</td><td>VAT T1 (n = 111)</td><td>VAT T2 (n = 112)</td><td>VAT T3 (n = 111)</td><td>VAT T1 (n = 40)</td><td>VAT T2 (n = 41)</td><td>VAT T3 (n = 41)</td></tr></table> | <table><tr><td>Calcified plaque</td><td>1.7 ± 2.3</td><td>2.1 ± 2.7</td><td>3.0 ± 3.1*†</td><td>3.4 ± 3.4</td><td>3.3 ± 3.3</td><td>4.8 ± 3.7</td></tr><tr><td>Noncalcified plaque</td><td>0.7 ± 1.3</td><td>1.3 ± 1.6*</td><td>1.6 ± 2.0*</td><td>2.1 ± 2.2</td><td>2.0 ± 2.2</td><td>2.4 ± 2.1</td></tr><tr><td>Mixed plaque</... |
1af6852f229bbcd9d07b5c0fed52bc497c857c18e472ad593bc85610806d25e6.png | simple | <table><tr><td></td><td>Grenoble (n = 232)</td><td>Montpellier (n = 128)</td><td>Paris (n = 272)</td><td>Total (n = 632)</td></tr><tr><td>Genotype, %</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>16.8</td><td>21.9</td><td>15.4</td><td>17.3</td></tr><tr><td>AG</td><td>47.0</td><td>46.9</td><td>49.6</td... | <table><tr><td></td><td>Grenoble (n = 232)</td><td>Montpellier (n = 128)</td><td>Paris (n = 272)</td><td>Total (n = 632)</td></tr></table> | <table><tr><td>Genotype, %</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>16.8</td><td>21.9</td><td>15.4</td><td>17.3</td></tr><tr><td>AG</td><td>47.0</td><td>46.9</td><td>49.6</td><td>48.1</td></tr><tr><td>GG</td><td>36.2</td><td>31.3</td><td>34.9</td><td>34.7</td></tr><tr><td>Allele, %</td><td></td><... |
4d9f9af861cc3546d23538fa3ddcf669fb9ca2caea203837656f0e84fb99f0b2.png | simple | <table><tr><td>Factor</td><td>Score</td></tr><tr><td>Vascular invasion</td><td></td></tr><tr><td> no</td><td>0</td></tr><tr><td> yes</td><td>2.6</td></tr><tr><td>BCLC stage</td><td></td></tr><tr><td> 0-A</td><td>0</td></tr><tr><td> B-C</td><td>1.3</td></tr><tr><td>MiR-145</td><td></td></tr><tr><td> negative</td><td>0</... | <table><tr><td>Factor</td><td>Score</td></tr><tr><td>Vascular invasion</td><td></td></tr><tr><td>no</td><td>0</td></tr><tr><td>yes</td><td>2.6</td></tr><tr><td>BCLC stage</td><td></td></tr><tr><td>0-A</td><td>0</td></tr><tr><td>B-C</td><td>1.3</td></tr><tr><td>MiR-145</td><td></td></tr><tr><td>negative</td><td>0</td></... | <table><tr><td>negative</td><td>0</td></tr><tr><td>positive</td><td>1.7</td></tr><tr><td>MiR-92a</td><td></td></tr><tr><td>negative</td><td>0</td></tr><tr><td>positive</td><td>1</td></tr></table> |
58005f8928fb67fd24a5bd42182e6f931a247f2f76c160989cadfe0111b366f1.png | simple | <table><tr><td></td><td>Exercise Sample</td><td>Physical Activity Sample</td></tr><tr><td>GoF</td><td>.412 [.436]</td><td>.554 [.564]</td></tr><tr><td>APC</td><td>.218; <i>p</i> < .001 [.207; <i>p</i> < .001]</td><td>.291; <i>p</i> < .001 [.252; <i>p</i> <. 001]</td></tr><tr><td>ARS</td><td>.195; <i>p</i> =... | <table><tr><td></td><td>Exercise Sample</td><td>Physical Activity Sample</td></tr><tr><td>GoF</td><td>.412 [.436]</td><td>.554 [.564]</td></tr><tr><td>APC</td><td>.218; p < .001 [.207; p < .001]</td><td>.291; p < .001 [.252; p <. 001]</td></tr></table> | <table><tr><td></td><td>Exercise Sample</td><td>Physical Activity Sample</td></tr><tr><td>ARS</td><td>.195; p = .001 [.215; p < .001]</td><td>.361; p < .001 [.367; p < .001]</td></tr><tr><td>AFVIF</td><td>1.242 [1.981]</td><td>1.468 [1.961]</td></tr></table> |
8af71613ecb69d4c94e59ae07236a24faf7ec2bf7200c2e3bc6344688731df7f.png | simple | <table><tr><td>Time for data collection</td><td>Participants in the interviews</td></tr><tr><td>May–September 2013</td><td>Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24</td></tr><tr><td>May–September 2014</td><td>Unit managers, n = 5Officials, n = 16</td></tr></table> | <table><tr><td>Time for data collection</td><td>Participants in the interviews</td></tr></table> | <table><tr><td>May–September 2013</td><td>Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24</td></tr><tr><td>May–September 2014</td><td>Unit managers, n = 5Officials, n = 16</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.